Can sorafenib cause hypothyroidism?

摘要

Sunitinib, a multiple tyrosine kinase inhibitor with antiangiogenic properties has been reported to be associated with hypothyroidism in- 57-85% of treated patients, though the mechanism is unclear . Sunitinib and imatinib have even been reported to cause hypothyroidism in patients already on replacement levothyroxine for prior thyroidectomy . We report a 53-year-old woman with non-functional metastatic islet cell carcinoma treated with sorafenib, a novel multiple tyrosine kinase inhibitor, in the context of a IRB-approved clinical trial (MC044H), with resultant development of hypothyroidism. Our patient initially presented to our institution with a sudden exacerbation of a chronic non-specific epigastric pain. She was found to have metastatic pancreatic islet cell carcinoma with liver metastases. Due to lack of symptoms, she was observed for three years prior to initiation of therapy, which was done due to slow progression. She initially received gefitinib in a clinical trial, but progressed after 6 months.